in a Pandemic
2020 Virtual Nanomedicine Symposium
Thank you to all the participants, look for our next Symposium coming next fall.
With over 800 attendees, 300 questions asked and answered, and 13 speakers, you made PNI's first Virtual Nanomedicine Symposium a great success!
We will be sending out links to the sessions in the first week of August for those who attended the symposium and would like links to the recorded sessions.
If you could not attend the and would like to learn more about nanomedicine and view the recordings from the symposium, please fill out the form below, and we will be in touch with you.
Dr. Luis Brito
Dr. Luis Brito's research interest is focused on developing delivery systems for therapeutics and vaccines. He is currently Director of Formulation Design at Moderna Therapeutics where he oversees a team of scientists focused on optimizing formulations for mRNA. Prior to Moderna he was a Head of Formulation Science at Novartis Vaccines and Diagnostics where he was responsible for early discovery of adjuvant formulations and mRNA vaccine delivery systems. He has co-authored 30 peer reviewed journal articles and is an inventor on 26 patents.
Dr. Gaurav Sahay
Oregon State University
Gaurav Sahay is an Assistant Professor in the Department of Pharmaceutical Sciences, College of Pharmacy at Oregon State University. Dr. Sahay’s lab is developing novel nanotechnology-based platforms for effective delivery of messenger RNA therapeutics for treatment of rare disorders including cystic fibrosis, retinal degeneration and lysosomal storage disorders. He has done pioneering work to dissect the intracellular transport essential for nucleic acid delivery to the cytosol and developed methods to overcome endosomal barriers. He has more than 43 peer-reviewed publications in top tier journals including Nature, Nature Biotechnology, Nature Nanotechnology, Journal of Controlled Release, Nano Letters.
Dr. Yvonne Perrie
University of Strathclyde
Dr. Perrie is a Professor in Drug Delivery at the University of Strathclyde as part of the Global Talent Appointment Programme. She is an internationally recognised expert in the field of liposomes and particulate drug delivery research with a strong track-record of high impact publications, with approximately 130 peer reviewed manuscripts plus 5 textbooks. Her research and academic leadership has been recognised via a range of fellowships and awards including the Royal Pharmaceutical Society Harrison Memorial Medal (2019), 50th Anniversary Chair in Drug Delivery (2016), membership of the Controlled Release Society College of Fellows (2015), Fellow of the Royal Pharmaceutical Society (2014), Fellow of the Royal Society of Biology (2012), Eminent Fellow of the Academy of Pharmaceutical Sciences (2012), the Royal Pharmaceutical Society Pharmaceutical Scientist of the Year (2012), the British Science Festival Collaboration in Formulation Award (2011) and the Royal Pharmaceutical Society Science Conference Medal (2007).
Dr. Frank Slack
Harvard Medical School
Dr. Frank Slack is the Shields Warren Mallinckrodt Professor, Department of Pathology, and Director of the Institute for RNA Medicine, BIDMC. He began work on microRNAs as a postdoctoral fellow in Gary Ruvkun’s laboratory at Harvard Medical School, where he co-discovered the second known microRNA, let-7. The Slack laboratory is at the forefront of the small RNA revolution. They co-discovered the first human microRNA, let-7 and showed that it is a tumor suppressor that controls key cancer genes, such as RAS, MYC and LIN28. They are developing let-7 and a second microRNA, miR-34 as novel cancer therapeutics with miR-34 already in Phase I clinical trials. They also proved that microRNAs act as key oncogenes and developed strategies to target these oncomiRs for cancer therapy. Their research also extends to discovery of additional novel small RNAs in development, cancer, aging and diabetes as well as identifying novel SNPs in the non-coding portions of the genome with an eye to identifying the next generation of actionable targets in cancer.
Dr. G Brett Robb
New England Biolabs
Dr. Brett Robb heads up a group of research teams at New England Biolabs who are focused on discovery, development, and commercialization of enabling enzyme-based technologies. Brett’s past and current work spans many areas of RNA science including mRNA stability, RNA-guided enzymes, and post-transcriptional RNA modifications.
Dr. Bijoyita Roy
New England Biolabs
Dr. Bijoyita Roy is an RNA biologist with a longstanding interest in understanding the various aspects of post-transcriptional gene regulation. As a Staff Scientist at New England Biolabs, Bijoyita is leading a basic and applied research program focused on applications for synthetic modified RNA, with an emphasis on the discovery, identification, and evaluation of mRNA synthesis tools and technologies.
Dr. Anton McCaffrey
Trilink Biotechnologies, Inc.
Dr. Anton McCaffrey is the Senior Director of Emerging Science and Innovation at TriLink BioTechnologies and an adjunct Assistant Professor of Internal Medicine at the University of Iowa. Dr. McCaffrey has over 25 years of experience designing nucleic acid-based therapeutics for antisense, RNA interference, aptamer and genome editing applications. He joined TriLink in 2011 and helped establish the company’s program for manufacturing GMP grade mRNAs for genome editing, gene replacement and vaccines. His research focuses on genome editing with zinc-finger nucleases, self-amplifying RNA replicons, microRNAs and RNA interference targeting hepatitis viruses. His other research interests include scalable mRNA manufacturing processes, rapid manufacturing of RNA based vaccines, chemical modification of mRNA to reduce innate immune stimulation, the biology of 5’ caps and the development of specialized assays for mRNA characterization.
Jessica Madigan is Director of Business Development at TriLink BioTechnologies. Jessica played a pivotal role in the pioneering of contract messenger RNA manufacturing and served as manufacturing support lead for groundbreaking programs in mRNA therapeutics. With unparalleled experience and expertise, she has successfully guided over 20 therapeutic companies into clinical programs. For over a decade at TriLink, Jessica has worked in customer and technical service across a variety of product types and application areas of focus, including vaccine development, gene and cell therapy, and protein replacement therapies. Additionally, Jessica leads ConsultLink™, a signature program that provides a skilled team of experts to work alongside your project team throughout the duration of your GMP manufacturing process. She received her B.Sc. in chemistry/biochemistry from the San Diego State University and is certified as a Project Management Professional.
University of Washington
Annie Dosey is a fourth year PhD student in the laboratory of Dr. Neil King in the Institute for Protein Design at the University of Washington. Our lab uses protein design to develop novel protein-based nanomaterials that are the basis for our vaccine platform. My work is focused around antigen design, immune refocusing techniques, as well as probing the mechanisms of immune responses elicited by our nanoparticle immunogens.
Dr. Andy Geall
Dr. Andy Geall joined the PNI team as a Chief Scientific Officer in March. He is renowned for leading the RNA nanoparticle vaccine platform at Novartis and was the Principal Investigator on a DARPA contract to apply the technology towards pandemic response.
Dr. Lloyd Jeffs
Dr. Lloyd Jeffs is the Director of Clinical Manufacturing at PNI and has played key roles in GMP manufacturing of RNA-LNP for over 10 clinical-stage programs including an RNA-based Ebola drug for the US Army.
Dr. Suraj Abraham
Dr. Suraj Abraham is an experienced pharmaceutical scientist and a bioengineer, who has more than ten years of experience in the field of drug discovery and drug product development focused on transformative patient-centric personalised medicine. His PhD work at the University of Saskatchewan, Saskatoon, Canada was on developing a novel in vitro 3D co-culture based experimental model for testing anti-scarring and wound modulating agents. His subsequent post-doctoral training was on cancer immunotherapy and nano-theranostics formulation development. Before joining PNI's Formulation R&D team, Suraj worked in the regenerative medicine industry for over five years as a Product Development Scientist and Projects Manager at the New World Laboratories Inc, Canada. At PNI, Suraj is involved in several R&D research activities around developing novel drug delivery systems and clinical-grade lipid/polymer nanoparticles for regenerative medicine applications using PNI’s proprietary NxGen technology.
Dr. Shell Ip
Dr. Ip is currently the Scientific Applications Liaison at Precision Nanosystems has been serving in technical communication and training roles in PNI's commercial team since 2015. He combines his multidisciplinary background with an aptitude for communication to convey complex concepts to diverse audiences through various media. In his postdoctoral and doctoral research, he developed hybrid bio/inorganic nanomaterials for diagnostics applications. He has earned a Ph.D. in Chemistry and a B.A.Sc. in Engineering Science and from the University of Toronto.
Dr. Jason Coleman
Dr. Jason Coleman is a Field Application Scientist for PNI, supporting the Mid-Atlantic region of the United States and Eastern Canada. Prior to joining PNI, he worked as an Associate Director, leading a team focused on the integration of a nanoparticle-based platform for the delivery of small molecules for bioavailability enhancement. He was the lead scientist on the development of a prostate cancer drug that was commercially approved on this platform. Overall, Dr. Coleman has over 10 years of experience in the pharmaceutical and biotech industries and has specialized in both nanoparticle platform drug development and process scale-up.
Dr. Anastasia Darwitan
Dr. Anastasia Darwitan has extensive experience in formulation of lipid-based nanocarriers for drug delivery in various therapeutic areas. She developed formulations for cardiovascular disease treatment as well as studied the effect of surface functionalization on diseased cell uptake during her time at Nanyang Technological University. Dr. Darwitan currently serves as Field Application Scientist for Precision Nanosystems, covering the APAC region.
Dr. Viet Anh Nguyen Huu
Dr. Nyugen Huu devised formulations for ocular drug delivery and studied mechanisms of age-related eye disorders during his time at the University of California, San Diego. He has extensive expertise in formulation techniques including polymers, small molecules and proteins, as well as experience in analytical instrumentation and assays to characterize these constructs. Dr. Nguyen Huu currently serves as a Field Application Scientist for Precision Nanosystems
Dr. Piyush Kapoapra
Dr. Piyush Kapoapra is a nanomedicine scientific specialist and a pharmacist with over eight years of pre-clinical and target discovery research experiences in diverse therapeutic areas. Previously, he was a postdoctoral research fellow at Dept. of Medicine, UBC, Vancouver, working on finding novel therapeutic targets for thrombotic diseases. He completed his Ph.D. in Molecular Medicine from Hannover Medical School in Germany where his research focused on cell signaling pathways implicated in cardiovascular disease identifying a protein kinase as a potential drug target to prevent vascular remodeling and heart failure.
Martin Rabel is a pharmacist by training and currently serves as the Field Application Scientist for PNI covering EMEA south. He has extensive experience across various nanoparticle formulation techniques, analytical methods and applications. After obtaining his post-graduate diploma working on bacterial nanocellulose particles for gene delivery applications, he started his PhD training at the FSU Jena, Germany, working on iron oxide nanoparticles for imaging applications. After working in a public pharmacy and as a drug safety manager, he joined the PNI team in 2019.
Dr. Deo Tiwari
Dr. Deo Tiwari is a Scientific Specialist at Precision NanoSystems Inc. (PNI) and helps clients understand how PNI’s microfluidic technology can help with their nanoparticle formulations. In his doctoral and postdoctoral research, he worked upon numerous projects based on small molecule-based drug discovery. Dr. Tiwari completed his PhD from Indian Institute of Technology Kanpur, India and had postdoctoral research experience in Israel (Weizmann Institute of Science), Germany (RWTH Aachen University, Humboldt fellow) and Canada (University of British Columbia).
Aditya Upadhyay completed his B.E. in Biotechnology at Agra University. Following his degree, he was involved on a project on molecular cloning techniques, including restriction, digestion, ligation, bacterial transformation and protein expression. His expertise lies in technical sales and commercial launch of innovative life-sciences products and services in global markets. He has extensive experience of working with leading genomics companies building their market in more than 18 countries, bringing next generation sequencing from research to clinical use.
Dr. Imran Vhora
Dr. Imran Vhora works with PNI’s Formulation Solutions group as a Scientific Specialist. He has 10 years of formulation development experience with expertise on various lipid-based and polymeric particulate systems. He has worked with various pharmaceutical industry clients in India to develop proprietary and generic products during his PhD tenure. After graduation, he joined as a Scientist at Dr. Reddy’s Labs developing 505(b)2 injectable and nasal combination products for US market and then undertook postdoctoral research at Florida A&M University on ocular and injectable nanoparticles. Before joining PNI, he worked as a Lead Scientist at Ascension Bioceuticals for developing lipid nanoemulsions.
Dr. Ian Villamagna
Dr. Villamagna led the development of multiple drug delivery formulations for the treatment of osteoarthritis during his time at the University of Western Ontario. He has extensive experience in the nanomedicine development process, beginning with formulation of new biomaterials, and ending with leading large animal trials. Dr. Villamagna currently serves as the Field Application Scientist for PNI, covering the Northwestern United States and Western Canada.
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.